Publications by authors named "Johan Baeck"

Claim this Profile
A
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.
Taxiarchis Kourelis, Sikander Ailawadhi, Dan T Vogl, Sarah E Gibson, Meaghen E Sharik, Johan Baeck

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Johan Baeck

Clin Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.
Kyriakos P Papadopoulos, Nehal Lakhani, Gerald S Falchook, Gosia Riley, Johan Baeck

Cancer Immunol Immunother· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Anna Forsythe, David Chandiwana, Janina Barth, Marroon Thabane, Johan Baeck

Breast Cancer (Dove Med Press)· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
Anna Forsythe, David Chandiwana, Janina Barth, Marroon Thabane, Johan Baeck

Cancer Manag Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.
Michelle Fanale, Sarit Assouline, John Kuruvilla, Philippe Solal-Céligny, Dae S Heo, Johan Baeck

Br J Haematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.
John C Byrd, Thomas J Kipps, Ian W Flinn, Maureen Cooper, Olatoyosi Odenike, Johan Baeck

Leuk Lymphoma· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
William Bensinger, Richard T Maziarz, Sundar Jagannath, Andrew Spencer, Simon Durrant, Johan Baeck

Br J Haematol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis